During the study period (2003–2019), several novel therapies for CNS tumors were introduced, including anti-VEGF agents such as bevacizumab and regorafenib, temozolomide (TMZ) in combination with radiotherapy, and tumor-treating fields (TTF) [51,52,53,54]. Here, VEGFA is linked to central nervous system neoplasm.